Japan Digestive Disease Week 2025
International Poster Session1 (JDDW)
October 31, 9:30–10:18, Room 15 (Kobe International Exhibition Hall No.1 Building Digital Poster Venue)
IP-3_E
Chemoradiotherapy versus Surgery as Salvage Treatment for cT1N0M0 Esophageal Squamous Cell Carcinoma Diagnosed as pT1b-SM2 after ESD: Long-Term Clinical Outcomes
- 1
- Department of Endoscopy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Objective:
The aim of this study was to compare the long-term outcomes of chemoradiotherapy (CRT) and surgery as additional treatments for patients with pT1b-SM2 esophageal squamous cell carcinoma (ESCC) following endoscopic submucosal dissection (ESD).
Methods:
This retrospective study analyzed patients with cT1N0M0 ESCC who underwent ESD at our department between April 2014 and April 2019. Patients diagnosed with pT1b-SM2 after ESD and subsequently treated with CRT or surgery were included. Overall survival (OS) and recurrence-free survival (RFS) were compared between the two groups.
Results:
A total of 39 patients were included, comprising 28 treated with CRT and 11 who underwent esophagectomy. The median follow-up period was 70.7 months. The 5-year OS rates were 85.7% in the CRT group and 90.9% in the esophagectomy group, while the 5-year RFS rates were 71.4% and 81.8%, respectively. No statistically significant differences in OS or RFS were observed between the two groups. Similarly, among high-risk patients with lymphovascular invasion, no significant differences in OS or RFS were found.
Conclusion:
For patients with cT1N0M0 ESCC diagnosed as pT1b-SM2 following ESD, CRT as additional treatment may provide long-term outcomes comparable to those of esophagectomy.
The aim of this study was to compare the long-term outcomes of chemoradiotherapy (CRT) and surgery as additional treatments for patients with pT1b-SM2 esophageal squamous cell carcinoma (ESCC) following endoscopic submucosal dissection (ESD).
Methods:
This retrospective study analyzed patients with cT1N0M0 ESCC who underwent ESD at our department between April 2014 and April 2019. Patients diagnosed with pT1b-SM2 after ESD and subsequently treated with CRT or surgery were included. Overall survival (OS) and recurrence-free survival (RFS) were compared between the two groups.
Results:
A total of 39 patients were included, comprising 28 treated with CRT and 11 who underwent esophagectomy. The median follow-up period was 70.7 months. The 5-year OS rates were 85.7% in the CRT group and 90.9% in the esophagectomy group, while the 5-year RFS rates were 71.4% and 81.8%, respectively. No statistically significant differences in OS or RFS were observed between the two groups. Similarly, among high-risk patients with lymphovascular invasion, no significant differences in OS or RFS were found.
Conclusion:
For patients with cT1N0M0 ESCC diagnosed as pT1b-SM2 following ESD, CRT as additional treatment may provide long-term outcomes comparable to those of esophagectomy.
- Index Term 1: Esophageal squamous cell carcinoma
- Index Term 2: Endoscopic submucosal dissection